SEC Tracker
Get the app

Synlogic SYBX

Synlogic (SYBX) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational status. The filing highlights the company's ongoing research and development efforts in its pipeline of synthetic biology-based therapeutics, which are critical to Synlogic's long-term growth and competitive positioning within the biotechnology industry. Investors will closely monitor this report for insights into the company's progress, cash position, and any potential milestones or setbacks that could impact the stock's valuation.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Synlogic files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
  2. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  3. Soligenix SNGX public float $5M, Jun 30, 2025
  4. Target Group CBDY public float $5M, Jun 30, 2025
  5. Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.